Cyclo Therapeutics Q1 2024 GAAP EPS $(0.15) Beats $(0.19) Estimate, Sales $202.450K Miss $376.667K Estimate
Portfolio Pulse from Benzinga Newsdesk
Cyclo Therapeutics (NASDAQ:CYTH) reported a Q1 2024 GAAP EPS of $(0.15), beating the analyst estimate of $(0.19). However, sales of $202.450K missed the $376.667K estimate, despite a 32.83% increase from the same period last year.
May 16, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cyclo Therapeutics reported a Q1 2024 GAAP EPS of $(0.15), beating the analyst estimate of $(0.19). However, sales of $202.450K missed the $376.667K estimate, despite a 32.83% increase from the same period last year.
The EPS beat is a positive sign, but the significant miss on sales estimates could offset the positive sentiment. The YoY sales increase is a positive factor, but the overall impact on the stock price is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100